UK promises 67-day Brexit licence for biologicals and biosimilars

Manufacturers of new biological or biosimilar medicines could obtain a licence to sell their medicines in the UK within 67 days of making an application under a new scheme aimed at minimising the impact of a ‘no deal’ Brexit.